Future Mental Projections in Schizophrenia (FutureProSchiz)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Fabrice BERNA, MD
- Phone Number: 0033388116462
- Email: fabrice.berna@chru-strasbourg.fr
Study Locations
-
-
-
Strasbourg, France, 67000
- Service de psychiatrie 1
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- for patients only
- male or female
- age limits : 18-55 years old
- under the protection of health insurance
- who have signed up the consent form
- schizophrenia or schizo-affective disorder according to the DSM-5 criteria (APA, 2013).
- clinically stable for at least 2 months
- patients under guardianship or curatorship need agreement of their legal representative
- informed of the results of prior medical examination for controls only
- male or female
- age limits : 18-55 years old
- under the protection of health insurance
- who have sign up the consent form
- recruited from the general population and matched on gender, age years of schooling
- no psychiatric history (DSM-5)
Exclusion Criteria:
- for both patients and controls
- current severe or unstable somatic illness
- neurological history (brain injury > 15 minutes loss of consciousness , epilepsia, brain surgery…)
- current substance use disorder (DSM-5)
- current major depressive disorder (CDSS,BDI, HDRS)
- mental retardation (IQ < 70, WAIS-4, f-NART)
- history of general anesthesia 3 months prior to the experiment
- pregnancy declared by the subject
- breast feeding
- current legal control
- in emergency situation
- included during exclusion period in another experiment
- for controls only
- taking of antipsychotic drugs for the 3 weeks prior to inclusion
- under guardianship or curatorship
Study Plan
How is the study designed?
Design Details
- Observational Models: Other
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Patients with schizophrenia
Patients with schizophrenia or schizoaffective disorder according to DSM-V criteria
|
Participant's verbalization will be audio recorded and then transcribed by investigators.
The investigators will use predefined categories to score the strategies mentioned by participants during the think aloud task.
|
|
Control participants
- Control participants without psychiatric nor neurological history
|
Participant's verbalization will be audio recorded and then transcribed by investigators.
The investigators will use predefined categories to score the strategies mentioned by participants during the think aloud task.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number of time location strategies
Time Frame: 1 months
|
1 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 6527
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Schizophrenia
-
NCT07369401Not yet recruiting
-
NCT01190254CompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
NCT07184619Recruiting
-
NCT01190267CompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
NCT05944510CompletedTreatment Resistant Schizophrenia
-
NCT07652866Not yet recruiting
-
NCT07154407Not yet recruitingSchizophrenia Disorder
-
NCT07626034Not yet recruiting
Clinical Trials on questionnary
-
NCT04385121CompletedDepression | Covid-19 | Stress Disorders, Post-Traumatic | Anxiety
-
NCT05617781CompletedPost-traumatic Stress Disorder | Mental Disorder | Empathy
-
NCT05701020CompletedSexual Dysfunction | Epidemiology
-
NCT04000802CompletedDecision Making | Quality of Health Care | Patient Care Team | Neoplasms/Therapy
-
NCT06448260CompletedWalking, Difficulty | Amputation, Surgical
-
NCT01782248UnknownAlzheimer Disease | Fronto-temporal Lobar Dementia
-
NCT03801018UnknownAssisted Reproductive Techniques
-
NCT05400200CompletedStress Disorders, Post-Traumatic
-
NCT06815107RecruitingTolerance | Urinary Symptoms | Ureteral Double-J Stent